

Role of Inflammation in Depressive and Anxiety Disorders, Affect, and Cognition: Genetic and Non-Genetic Findings in the Lifelines Cohort Study.

Naoise Mac Giollabhui

tug15671@temple.edu

Massachusetts General Hospital <https://orcid.org/0000-0003-4226-5704>

Chloe Slaney

Gibran Hemani

Eimear Foley

University of Bristol <https://orcid.org/0000-0002-3603-3774>

Peter van der Most

<https://orcid.org/0000-0001-8450-3518>

Ilja Nolte

University of Groningen, University Medical Center Groningen <https://orcid.org/0000-0001-5047-4077>

Harold Snieder

University Medical Center Groningen <https://orcid.org/0000-0003-1949-2298>

George Davey Smith

University of Bristol <https://orcid.org/0000-0002-1407-8314>

Golam Khandaker

Bristol Medical School

Catharina Hartman

<https://orcid.org/0000-0002-8094-8859>

Article

Keywords:

Posted Date: August 10th, 2024

DOI: <https://doi.org/10.21203/rs.3.rs-4379779/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Additional Declarations: The authors have declared there is **NO** conflict of interest to disclose

Abstract

Inflammation is associated with a range of neuropsychiatric symptoms; however, the nature of the causal relationship is unclear. We used complementary non-genetic, genetic risk score (GRS), and Mendelian randomization (MR) analyses to examine whether inflammatory markers are associated with affect, depressive and anxiety disorders, and cognition. We tested in $\approx 55,098$ (59% female) individuals from the Dutch Lifelines cohort the concurrent/prospective associations of C-reactive protein (CRP) with: depressive and anxiety disorders; positive/negative affect; and attention, psychomotor speed, episodic memory, and executive functioning. Additionally, we examined the association between inflammatory GRSs (CRP, interleukin-6 [IL-6], IL-6 receptor [IL-6R and soluble IL-6R (sIL-6R)], glycoprotein acetyls [GlycA]) on these same outcomes ($N_{\max}=57,946$), followed by MR analysis examining evidence of causality of CRP on outcomes ($N_{\max}=23,268$). In non-genetic analyses, higher CRP was associated with a depressive disorder, lower positive/higher negative affect, and worse executive function, attention, and psychomotor speed after adjusting for potential confounders. In genetic analyses, CRP_{GRS} was associated with any anxiety disorder ($\beta = 0.002$, $p = 0.037$) whereas $GlycA_{GRS}$ was associated with major depressive disorder ($\beta = 0.001$, $p = 0.036$). Both CRP_{GRS} ($\beta = 0.006$, $p = 0.035$) and $GlycA_{GRS}$ ($\beta = 0.006$, $p = 0.049$) were associated with greater negative affect. Inflammatory GRSs were not associated with cognition, except sIL-6R_{GRS} which was associated with poorer memory ($\beta = -0.009$, $p = 0.018$). There was weak evidence for a CRP-anxiety association using MR ($\beta = 0.12$; $p = 0.054$). Genetic and non-genetic analyses provide consistent evidence for an association between CRP and negative affect. These results suggest that dysregulated immune physiology may impact a broad range of trans-diagnostic affective symptoms.

Introduction

Depression is the leading cause of mental health-related global disease burden ^{1,2}. Persistent cognitive problems, such as poor memory and concentration, are reported in 11% of adults aged ≥ 45 years ³ and are frequently observed across physical [cancer (35%); COVID-19 (22%); HIV (43%); hepatitis C (50%)] ⁴⁻⁷ and mental health conditions [depression (30%); schizophrenia (50%)] ^{8,9}. Existing treatments for depression are only modestly effective ¹⁰ and almost nonexistent for cognitive dysfunction ¹¹. A mechanistic understanding of depression and cognitive dysfunction is urgently needed to inform the development of effective treatments and prevention approaches.

Chronic, low-grade systemic inflammation may represent one such mechanism. Indices of inflammation [e.g., circulating levels of cytokines (e.g., interleukin-6 (IL-6) and acute phase proteins (e.g., C-reactive protein (CRP))] are elevated in individuals with depression compared to controls ¹² and inflammatory biomarkers have been linked to specific aspects of depression, such as anhedonia and negative affect ^{13,14}. Further, longitudinal observational studies have found that higher levels of inflammatory biomarkers (e.g., IL-6, CRP) are prospectively associated with higher depressive symptoms ¹⁵. Observational studies have linked inflammation with impaired cognition in population-based ¹⁶⁻¹⁹ and in physical ²⁰⁻²² and mental health conditions ²³⁻²⁶. Inflammation also impacts neural circuitry relevant to affective disorder and cognitive task performance ^{27,28}, particularly the hippocampus ²⁹ and striatum ³⁰⁻³². To date, inflammation-cognition research has primarily relied upon observational data.

Inferring causality from observational studies is a challenge due to confounding (e.g., stress, poor sleep ²²) and reverse causality (i.e., whether inflammation impacts depression/cognition, or vice versa). Mendelian randomization (MR) is a genetic epidemiological method that can test causal relationships by using genetic variants associated with an exposure (e.g., inflammation) as proxies for the exposure ³³. As genetic variants are randomly inherited from parents to offspring and are fixed at conception, they are less likely to be associated with confounders and overcome issues of reverse causation ³³. Preliminary evidence, using MR, implicate IL-6 and its soluble IL-6 receptor (sIL-6R) in depression ³⁴⁻³⁷. To date, most MR studies examining the effect of IL-6 on health have focused on circulating IL-6 levels. However, IL-6 signals via multiple pathways (trans-signaling, classical-signaling, and trans-presentation) and there is growing evidence that IL-6 trans-signaling is primarily responsible for the pathogenic inflammatory effects of IL-6 ³⁸. Here, we include variants related to circulating IL-6 levels, and sIL-6R levels (relevant for IL-6 trans-signaling). Causal evidence for CRP and other proinflammatory markers [i.e., Glycoprotein Acetyls (GlycA) a composite biomarker thought to provide a more stable marker of inflammation which reflects the glycosylation of multiple acute-phase proteins ³⁹] on depression are mixed ^{34,37,40-43}. Regarding cognition, few studies have examined potential causal relationships with inflammation. MR analyses using available genome-wide association studies (GWAS) report both null results of inflammatory biomarkers on emotion recognition, working memory, response inhibition ⁴⁴ as well as effects of specific cytokines/chemokines (i.e., Eotaxin, IL-8) on fluid intelligence ⁴⁵.

The current study used data from the Lifelines Cohort Study – a large population-based cohort in the Netherlands – to conduct complementary non-genetic and genetic analysis to investigate the causal relationship between inflammation and negative affect, depressive disorders, and cognitive task performance. First, we used cross-sectional and longitudinal non-genetic analysis examine the association between circulating levels of CRP and depression/cognitive performance. Second, we conducted genetic risk score (GRS) and MR analysis to test whether genetic variants regulating levels and activity of CRP, IL-6, and GlycA were causally related with depression/cognitive performance. We also conducted the above analyses on closely related constructs (e.g., anxiety, negative/positive affect), for which associations with inflammation have previously been observed ⁴⁶⁻⁵¹ but for which considerably less empirical data has been published. We hypothesized that both circulating CRP levels and genetically predicted inflammatory biomarkers (i.e., CRP, IL-6, sIL-6R, and GlycA) would be associated with depression, cognitive task performance, affect, and anxiety.

Methods and Materials

Participants

Lifelines is a multi-disciplinary prospective population-based cohort study examining in a unique three-generation design the health and health-related behaviors of 167,729 persons living in the North of the Netherlands. It employs a broad range of investigative procedures in assessing the biomedical, socio-

demographic, behavioral, physical and psychological factors which contribute to the health and disease of the general population, with a special focus on multi-morbidity and complex genetics⁵². This cohort has previously been described in detail⁵². In brief, participants were recruited via their general practitioner (49%), participating family members (38%), and self-registration on the Lifelines website (13%). Exclusion criteria for recruitment through the general practitioner included: insufficient knowledge of Dutch language, severe psychiatric or physical illness, limited life expectancy (< 5 years). Baseline data included approximately: 140,000 adults (18–65 years), 15,000 children (0–17 years), 12,000 elderly individuals (65 + years). Following baseline assessment, participants are invited to complete an in-person study visit every 5 years. Phenotypic and genotypic data are collected by Lifelines to permit investigation on determinants of health. Data for the current study were drawn from 147,815 individuals who were aged 18 + years at baseline and who did not report a diagnosis that typically impairs cognitive function, specifically Alzheimer's disease, other dementias, epilepsy, multiple sclerosis, Parkinson's disease, and stroke. In the non-genetic analyses, the analytic sample is smaller as CRP was assessed in a sub-sample of individuals (N = 55,098) as was baseline cognitive performance on the Ruff Figural Fluency Test (N = 88,096). The analytic sample is smaller for non-genetic (N ≤ 55,098), GRS (N ≤ 57,946) and MR (N ≤ 23,268) analysis as only a subset of participants who met inclusion criteria had outcome data and CRP data (non-genetic analysis), genetic data (GRS), or genetic and CRP data (MR) due to time and cost constraints. Phenotypic data were drawn from both the baseline assessment and the first follow-up assessment; whether a specific measure was assessed at baseline, first follow-up or both assessments is noted for each measure.

Measures

Cognition

Ruff Figural Fluency Test (baseline assessment). The Ruff Figural Fluency Test (RFFT) is a reliable and valid measure of figural fluency, a dimension of executive function⁵³. Participants were asked to draw as many unique designs as possible within 60 seconds by connecting dots in different patterns. The task is composed of five parts, with each part containing 35 identical five-dot patterns (with or without distractors). The total number of unique designs was used as the dependent variable in the analyses, consistent with previous studies⁵⁴. In Lifelines, the RFFT was administered to all participants until April 2012, and subsequently in a random half of the sample. Data from participants who failed to generate a single unique design per trial ($n = 181$) were deemed invalid and removed.

Cogstate Test Battery (first follow-up assessment). The Cogstate Test Battery took approximately 10–15 minutes to complete and consisted of four tasks: detection task (psychomotor speed), identification task (attention), one-back task (working memory), and one card learning task (episodic memory). For each task, outcomes recommended by Cogstate were selected, specifically: log10 transformed response time in millisecond (detection/identification tasks) and arcsine-transformed response accuracy (one-back/one card learning tasks). For the detection and identification tasks, higher values reflect poorer performance and for the one-back and one card learning tasks, higher values equal better performance. Data cleaning involved excluding participants with a high number of errors. The percentage of successful trials per Cogstate task was high, averaging 66% ($n = 85,050$; $SD = .11$) on the episodic memory task, 91% ($n = 85,053$; $SD = .17$) on the visual attention task, 92% ($n = 85,053$; $SD = .20$) on the psychomotor speed task, and 90% ($n = 85,051$; $SD = .15$) on the working memory task. A small number of participants exhibiting implausibly low accuracy rates indicative of poor effort, failure to comprehend task instructions, or technical errors were excluded from analyses. Specifically individuals with an accuracy rate less than: 25% on the episodic memory task ($n = 231$), 40% on the visual attention task ($n = 2,878$), 45% on the psychomotor speed task ($n = 3,914$), and 35% on the working memory task ($n = 1,330$). For more details on the Cogstate Test Battery, see Supplementary Methods 1.1.

Clinical Assessments

Anxiety and Depressive Disorders (baseline/first follow-up assessments). The Mini International Neuropsychiatric Interview – Simplified (MINI) is a reliable, valid, and brief structured interview that was designed to screen for psychiatric disorders^{55–57}. Lifelines used an adapted version of a Dutch translation of the MINI that was administered by trained interviewers at baseline and self-administered on location at follow-up – details on the version used in Lifelines have previously been published⁵⁸. Participants were considered to meet criteria for any depressive disorder if they met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for Major Depressive Disorder (MDD) or dysthymia at the time of the interview. Impairment was assessed in the MINI for dysthymia but not depression and consequently, impairment was not used as a criterion for MDD. Any anxiety disorder refers to meeting current criteria for any one of the following conditions that was assessed using the MINI: panic disorder, agoraphobia, social phobia, or Generalized Anxiety Disorder (GAD). We used four diagnostic groups as outcome variables: MDD, any depressive disorder, GAD, and any anxiety disorder.

Positive and Negative Affect Schedule (baseline assessment). The Positive and Negative Affect Schedule (PANAS) assesses positive and negative affect⁵⁹ using two 10-item subscales (examples of items include 'excited' on positive subscale; 'upset' on negative subscale). Participants are asked to rate the extent that they experienced each item during the last four weeks on a five-point scale (ranging from 'not at all' to 'extremely'). The outcome is the summed score on each subscale, which ranges from 10 to 50 (higher value reflects higher positive or negative affect, respectively). The PANAS has been shown to be reliable and valid⁶⁰.

C-reactive Protein (baseline assessment)

Participants gave blood samples before 10AM via venipuncture following an overnight fast. Complete details on blood specimen data collection have previously been reported^{52, 54}. Due to assay costs, CRP was assessed in approximately 35% of Lifelines participants and data were available for 55,098 individuals in the analytic sample. CRP was quantified using three separate methods over the course of baseline assessment (Method 1: 12.90% of total CRP values assessed in serum; CardioPhase hsCRP; Method 2: 84.58% of total CRP values, assessed in plasma; CardioPhase high sensitivity (hs)CRP, Siemens Healthcare Diagnostics, Marburg, Germany; Method 3: 2.52% of total CRP values; assessed in plasma; CRPL3, Roche Diagnostics, Mannheim, Germany). Assay methods 2 and 3 were identical and only differed in terms of the manufacturer. A conversion formula ($\text{new} = 0.92 \times \text{old} - 0.01$) was derived from an internal validation using 39 samples, according to the AMC (alternative method comparison, Deming Regression) protocol in order that Method 1 could be

compared with Method 2 and 3⁵⁴. For CardioPhase hsCRP, the intra-assay coefficient of variability was 3.45% and the inter-assay coefficient of variability was 3.15%. For CRPL3, the intra-assay coefficient of variability was 4.15% and the inter-assay coefficient of variability was 5.8%.

Genetic Data

Genotype data were available for a subgroup of participants in Lifelines. Genotyping was conducted using three chip arrays: Illumina CytoSNP-12 Bead Chip v2 array (N = 17,033), Infinium Global Screening Array (GSA) Beadchip-24 v1.0 (N = 38,030), FinnGen Thermo Fisher Axiom® custom array (Affymetrix; N = 29,166). For details on quality checks (QC's) and imputation conducted by Lifelines, see Supplementary Methods 1.2. Following Lifelines QC's, the total sample size for participants who met criteria for this study: CytoSNP (N = 14,942), GSA (N = 31,810) and Affymetrix (N = 26,334). We applied additional QC's which included removing: one of the duplicates (individuals who were genotyped on more than one chip) and first-degree relatives between chips, non-European individuals (identified by Lifelines), and genetic outliers (identified by Lifelines); see Supplementary Fig. 1 for more details. This resulted in a total of 58,713 participants with genetics data included in this study (CytoSNP N = 7,632; GSA N = 24,975; Affymetrix N = 26,106). For more details on the genetic data in Lifelines, see Supplementary Methods 1.2.

Covariates

Covariates included age, sex, educational attainment, body mass index (BMI) and health status. Age, sex, and educational attainment were self-reported by participants. Educational attainment was determined using a single-item question and was categorized by Lifelines as: low [no education, primary education, lower/preparatory vocational education, lower general secondary education (leaving secondary school aged > 16 years)], moderate (intermediate vocational education/apprenticeship, higher secondary education), and high (higher vocational education, university). We recoded educational attainment so that higher values represent lower educational attainment. To estimate body mass index (BMI), height was measured to the closest 0.1 cm and body weight was measured without shoes to 0.1 kg precision. For health status, a composite measure was created counting several self-reported chronic medical conditions related to increased levels of inflammation (i.e., arthritis, asthma, coeliac disease, Crohn's disease, diabetes, and psoriasis); we then categorized participants into those with no relevant chronic medical condition, 1, 2 or 3 + conditions.

Analyses

Analyses were conducted in R version 4.1.1.

Non-genetic Analyses

Multivariable linear and logistic regression models were estimated using base functions in R (i.e., 'lm', 'glm'). CRP was transformed by natural log to impose a normal distribution.

Genetic Risk Scores

Genetic risk scores (GRS) were calculated to determine whether GRS for inflammatory markers (CRP, IL-6, IL-6R, sIL-6R, GlycA) were associated with depression/anxiety, affect and cognitive outcomes. To create GRS for each inflammatory marker, we identified genetic variants (single nucleotide polymorphisms [SNPs]) associated with these proteins in large available GWAS or using SNP lists from previous publications, see Supplementary Table 1. For details on the GWAS used and accessing summary statistics, please see Supplementary Methods 1.3 and Supplementary Tables 2–3. The following criteria were used to identify SNPs from GWAS for each inflammatory marker: p -value < 5×10^{-8} , linkage disequilibrium clumping ($r^2 = 0.01$, $kb = 1000$ based on the European-clustering individuals in the 1000 genomes reference panel) using *ld_clump()*⁶¹ in the *ieugwasr* package, minor allele frequency > 0.01. In the primary analysis, we restricted the SNP set to *cis* variants (SNPs ± 1 Mb from protein coding gene based on Genome Reference Consortium Human Build used in the GWAS)^{62–64}. The reason for restricting to *cis* variants in the primary analysis is because, due to their proximity to the protein coding gene, they are more likely to be valid instruments, as they are more likely to influence mRNA expression and protein levels (thus being less pleiotropic)⁶⁵. For GlycA, which does not have a single coding gene due to its composite nature, we used the largest available GWAS in our primary analysis. In our secondary analyses, we used both *cis* and *trans* variants from GWAS (i.e., we did not restrict to *cis* variants). Each SNP list was used to create a weighted GRS for each Lifelines participant. Specifically, the risk alleles were weighted by the effect size (beta) reported in the GWAS/previous study and then summed to provide a risk score. Any SNP identified in GWAS/previous study that was not available in Lifelines was replaced with a proxy (where possible) that had $r^2 > 0.8$ (using *LDproxy_batch* function in EUR population in R), rsID (SNP name) available, SNP available in full summary statistic GWAS, and in Lifelines^{66,67}. GRS were created in Plink v1.90⁶⁸ and continuous phenotypes were standardized within each chip (z-scored) for direct comparison (CRP levels were log transformed but not standardized).

To adjust for relatedness within each chip, two approaches were taken. The primary approach applied the GRAMMAR method⁶⁹ and the secondary approach involved re-running analyses removing close relatives (up to first-degree, up to second-degree, and up to third-degree), see Supplementary Materials 1.4 and 1.5 for details. We then ran regression models predicting each outcome using the standardized GRS, including top 10 genetic PCs (calculated on merged Lifelines genotype data), age, sex, and chip. Maximum sample size for analyses: no relatives within chips removed (N = 58,713), up to first-degree removed (N = 50,955), up to second-degree removed (N = 50,255), up to third-degree removed (N = 48,880). Unadjusted analyses are also reported in the Supplementary Tables 6 and 7.

Mendelian randomization

To conduct MR using individual level data and two-stage least squares regression, genetic data, exposure data, and outcome data are required. As only CRP is available within the Lifelines cohort (IL-6 and GlycA are not currently available), only this inflammatory marker could be assessed in the MR analysis. Where there was evidence of associations between CRP GRS and outcomes, we followed this up with MR to assess potential causality. Two-stage least squares regressions were conducted using the *AER* package⁷⁰. Analyses were GRAMMAR adjusted for relatedness and all regression models adjusted for age, sex,

and chip. To check MR assumptions, we ran linear regressions to test whether CRP GRS were associated with circulating CRP levels in participants with both genetic and CRP data available ($n = 23,607$) using the GRAMMAR method. We also checked whether any inflammatory marker GRS were associated with potential confounders (BMI, current smoking status, educational attainment; all models were adjusted for age, sex, and chip).

Results

The characteristics of the Lifelines cohort sample are described in Table 1 and Pearson correlations between study variables are presented in Table 2.

Table 1
Lifelines Cohort Sample Characteristics at Baseline and First Follow-up Assessment

Measures	Cohort Analyses (n = 147,815)	Genetic Analyses (n = 58,713)
Baseline Assessment		
Age [Mean (SD)]	44.52 (13.12) n = 147,815	43.04 (13.56) n = 58,713
Sex (% Female)	59% n = 147,815	60% n = 58,695
Education (N %)	n = 146,050	n = 58,112
- Lower	43,750 (30%)	16,359
- Moderate	57,785 (40%)	23,770
- Higher	44,515 (30%)	17,983
Body mass index	26.05 (4.34) n = 147,719	25.81 (4.27) n = 58,680
RFFT (Unique designs) [Mean (SD)]	81.50 (22.94) n = 88,096	82.46 (23.01) n = 36,563
Any Depressive Disorder (Current Major Depression or Dysthymia)	3.4% n = 141,045	2.9% n = 56,861
Major Depressive Episode (Current)	2.1% n = 141,538	1.8% n = 57,048
Any Anxiety Disorder (panic disorder, agoraphobia, social phobia, or GAD)	7.8% n = 141,538	7.2% n = 57,048
Generalized Anxiety Disorder	4.2% n = 141,539	3.8% n = 57,048
Negative Affect Score [Mean (SD)]	20.71 (13.12) n = 139,217	20.70 (5.22) n = 57,964
Positive Affect Score [Mean (SD)]	35.37 (4.25) n = 139,217	35.37 (4.19) n = 57,964
C-reactive protein level (mg/L), [Median (IQR), Mean (SD)]	1.2 (.60, 2.80), 2.61 (4.76) n = 55,098	1.2 (2.2) 2.62 (4.60) n = 23,607
First follow up		
Any Depressive Disorder (Current Major Depression or Dysthymia)	4.1% n = 77,758	Not used
Major Depressive Episode (Current)	3.0% n = 77,758	Not used
Any Anxiety Disorder (panic disorder, agoraphobia, social phobia, or GAD)	8.3% n = 77,758	Not used
Generalized Anxiety Disorder	5.9% n = 77,758	Not used
Cogstate: Episodic Memory (Accuracy), Mean (SD)	0.96 (0.12) n = 84,819	0.96 (0.12) n = 36,798
Cogstate: Working Memory (Accuracy), Mean (SD)	1.31 (0.19) n = 83,721	1.32 (0.19) n = 36,363

Measures	Cohort Analyses (n = 147,815)	Genetic Analyses (n = 58,713)
Cogstate: Visual Attention (Response Time), Mean (SD)	2.69 (0.09) n = 82,175	2.68 (0.09) n = 35,743
Cogstate: Psychomotor Speed (Response Time), Mean (SD)	2.56 (0.16) n = 81,139	2.55 (0.16) n = 35,314
Lower = no education, primary education, lower/preparatory vocational education, lower general secondary education; Moderate = intermediate vocational education/apprenticeship, higher secondary education; Higher = higher vocational education, university; IQR = Inter Quartile Range.		

Table 2
Bivariate Correlations of Study Variables for 147,815 Participants

Measure	2.	3.	4.	5.	6.	7.	8.	9.	10.	11.	12.	13.	14.	15.	16.	17.	18.
1. T1 CRP (log-transformed)	-0.03	-0.03	0.04	0.03	-0.07	0.04	0.03	0.03	-0.05	0.03	0.14	0.11	0.36	0.10	0.03	0.03	0.0
2. T2 Episodic Memory ^B	-	0.31	-0.16	-0.16	0.21	-0.02	-0.03	-0.05	-0.02	-0.19	0.01	0.22	-0.08	-0.04	-0.02	-0.01	-0.0
3. T2 Working Memory ^B		-	-0.17	-0.17	0.20	-0.02	-0.02	-0.04	.00 ^a	-0.20	-.01 ^a	-0.2	-0.07	-0.04	-0.02	0	-0.0
4. T2 Psychomotor Speed ^C			-	0.63	-0.30	.01 ^a	.00 ^a	0.04	.00 ^a	0.39	.00 ^a	0.21	0.08	0.04	0.01	-0.02	0.0
5. T2 Visual Attention ^C				-	-0.34	0.01	.00 ^a	0.05	-0.02	0.43	-0.01	0.20	0.09	0.05	0.02	-0.01	0.0
6. T1 RFFT					-	-0.04	-0.02	-0.07	-0.07	-0.32	0.03	-0.35	-0.11	-0.08	-0.04	-0.01	-0.0
7. T1 Depression						-	0.25	0.27	-0.2	-0.02	0.05	0.07	0.04	0.07	0.35	0.19	0.8
8. T2 Depression							-	0.21	-0.13	-0.05	0.03	0.05	0.03	0.05	0.20	0.41	0.2
9. T1 Negative Affect								-	-0.21	-0.05	0.17	0.08	-0.01	0.06	0.32	0.26	0.2
10. T1 Positive Affect									-	-0.02	-0.01	-0.1	-0.02	-0.02	-0.17	-0.13	-0.1
11. T1 Age										-	-0.04	0.23	0.19	0.09	-0.01	-0.06	-0.0
12. T1 Female											-	0.02	-0.06	0.03	0.07	0.07	0.0
13. T1 Education												-	0.17	0.08	0.06	0.03	0.0
14. T1 Body mass index													-	0.13	0.03	0.01	0.0
15. T1 Health Status														-	0.07	0.04	0.0
16. T1 ANX															-	0.28	0.3
17. T2 ANX																-	0.1
18. T1 MDE																	-
19. T2 MDE																	
20. T1 GAD																	
21. T2 GAD																	

Probability ^a = $P > .05$; ^B = higher values equal better performance; ^C = higher values equal poorer performance; T1 = Time 1 (Baseline); T2 = Time 2 (First Follow-up); Health Status. = Number of Medical Conditions Reported; for values $\leq .001$ and $\geq .001$, values were rounded to 0.

Association of CRP with affect, depressive and anxiety disorders, and cognition

The association of (log-transformed) CRP with: clinical outcomes (i.e., MDD, any depressive disorder, GAD, any anxiety disorder), positive and negative affect, and five cognitive measures [RFFT (executive functioning), detection task (psychomotor speed), identification task (attention), one-back task (working memory), and one card learning task (episodic memory)] are illustrated in Table 3, both unadjusted and adjusted for covariates. Notably, CRP was associated with a greater likelihood of meeting criteria for a range of clinical outcomes, with a numerically greater likelihood consistently reported for depression as compared to anxiety at baseline and first follow-up assessment. However, these associations were attenuated after controlling for confounding by age, sex, education, health status, and BMI. Higher CRP was also associated with higher negative affect, lower positive affect, and worse cognitive task performance, although the magnitude of associations was generally very small and negligible after controlling for covariates.

Table 3

Associations of CRP levels with affect, depressive and anxiety disorders, and cognitive task performance in the Lifelines cohortPlease note: point estimates 95% confidence intervals (and N, p-value) as we do not currently have access to the Lifelines Cohort Workspace, the Cohort will allow us access to data for reviewer comments, we WILL add these (p-value, 95% CI, N) as necessary during review.

	Baseline							Follow-up						
Predictors	MDD	AnyDEP	GAD	Any ANX	Negative Affect	Positive Affect	RFFT	MDD	Any DEP	GAD	Any ANX	Psychomotor Speed	Attention	Episod Memori
	Odd's Ratio				Standardized regression coefficient			Odd's Ratio				Standardized regression coefficient		
Model 1 (Unadjusted analysis)														
CRP ^a	1.59	1.57	1.24	1.29	.03	− .05	− .07	1.43	1.42	1.26	1.22	.03	.03	− .03
Model 2 (Adjusted for age, sex, education, health status, and BMI)														
CRP ^a	1.02 [¶]	1.22	1.01 [¶]	1.06 [¶]	.01	− .04	− .03	1.06 [¶]	1.07 [¶]	1.05 [¶]	1.03 [¶]	.01	.01	0 [¶]
Age	.98	.98	.98	.99	− .06	0 [¶]	− .24	.97	.97	.97	.98	.38	.38	− .14
Female	1.53	1.59	1.56	1.66	.17	0 [¶]	.04	1.28	1.33	1.58	1.6	.01 [¶]	.01 [¶]	0 [¶]
Education: High	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Education: Moderate	1.62	1.76	1.3	1.28	.04	− .04	− .19	1.39	1.31	1.1 [¶]	1.12	.07	.07	− .13
Education: Low	2.94	3.02	1.64	1.72	.11	− .11	− .35	2.16	1.84	1.26	1.3	.16	.16	− .22
Health Status: 0 Dx	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Health Status: 1 Dx	1.83	1.64	1.55	1.43	.04	− .01	− .02	1.5	1.5	1.36	1.29	0 [¶]	0 [¶]	0 [¶]
Health Status: 2 Dx	2.97	2.63	2.26	1.82	.04	0 [¶]	− .02	2.5	2.34	1.67	1.47	0 [¶]	0 [¶]	− .01
Health Status: 3 + Dx	4.24	3.76	2.82	2.65	.02	− .01	− .01	3.71	3.28	2	1.67	0 [¶]	0 [¶]	− .01
BMI	1.04	1.03	1.01	1.01	0 [¶]	0 [¶]	0 [¶]	1.05	1.04	1.02	1.02	0 [¶]	0 [¶]	− .03

CRP = C-reactive Protein; MDD = Major Depressive Disorder; Any DEP = MDD or Dysthymia; GAD = Generalized Anxiety Disorder; Any ANX = panic disorder, ag social phobia, or GAD; RFFT = Ruff Figural Fluency Test; ^a = log-transformed variable; BMI = Body Mass Index; Ref = Reference Category for categorical variat > .05; Odds ratios are reported in logistic regression predicting binary outcomes and standardized beta coefficients are reported for linear regression; For va and ≥-.001, values were rounded to 0.

Associations of GRSs for inflammatory markers with affect, depressive and anxiety disorders

In the primary analysis, CRP_{GRS} (*cis*) was associated with a higher negative affect score (beta: 0.006; 95% CI: 0.0005 to 0.012, *p* = 0.035, N = 57,946) and increased risk of any anxiety disorder (beta: 0.002, 95% CI: 0.0001 to 0.004, *p* = 0.037, N = 57,047). GlycA_{GRS} was associated with higher negative affect score (beta: 0.006, 95% CI: 0.00002 to 0.012, *p* = 0.049; N = 57,946) and increased risk of MDD (beta: 0.001, 95% CI: 0.0001 to 0.002; *p* = 0.036; N = 57,047). Other inflammatory marker GRSs were not associated with depressive/anxiety disorders or affect scores (*ps* ≥ 0.15). In the secondary analysis, there was evidence that CRP_{GRS} (*genome-wide*) was associated with increased risk of any anxiety disorders (beta: 0.002, 95% CI: 0.0003 to 0.004, *p* = 0.023, N = 57,047). There was little evidence that other inflammatory marker GRSs were associated with depressive/anxiety disorders or affect (*ps* ≥ 0.16). For all results, see Fig. 1 and Supplementary Table 5. All sensitivity analyses removing differing degrees of related individuals (up to 1st -degree, up to 2nd -degree, up to 3rd -degree)

within chips (non-GRAMMAR method) did not substantially alter results, see Supplementary Tables 8–13. Although, there was slightly stronger evidence for associations between GlycA_{GRS} and negative affect score ($p \leq 0.015$) and between CRP_{GRS} (*cis*) and negative affect score ($p \leq 0.033$).

Association of GRS for inflammatory markers and cognition

In primary analyses, inflammatory marker GRSs were not associated with performance on cognitive tasks ($p \geq 0.14$), except for sIL-6R_{GRS} which was negatively associated with episodic memory performance (one card learning task accuracy; beta: -0.009, 95% CI: -0.017 to -0.002, $p = 0.018$, $N = 36,783$). In secondary analyses, inflammatory markers GRSs (*genome-wide*) were not associated with performance on cognitive tasks ($p \geq 0.22$). For all results, see Fig. 2 and Supplementary Table 5. Sensitivity analyses after removing related individuals within chips (non-GRAMMAR method) did not alter the results, see Supplementary Tables 11–13.

Testing potential causality between CRP, negative affect, and anxiety disorders using Mendelian randomization with individual level data

CRP genetic instruments had F-statistics > 10 (158 for *cis* GRS, 1045 for *genome-wide* GRS), indicating adequate instrument strength⁷¹. For tests on the MR assumptions, see Supplementary Results 2.2. There was weak evidence that genetically-proxied CRP (*cis*) causally increased the risk of any anxiety disorders (beta: 0.12, $p = 0.054$, $N = 22,154$), and little evidence on negative affect (beta: 0.27, $p = 0.16$; $N = 23,268$). Sensitivity analysis removing related individuals did not alter overall conclusions.

The overall pattern of results for the non-genetic and genetic analyses are visualized in Fig. 3.

Discussion

We conducted complementary non-genetic and genetic analyses to interrogate the relationship between inflammatory markers and affect, depressive and anxiety disorders, and cognitive task performance using data from the Lifelines cohort. In non-genetic analyses, higher CRP was associated with diagnosis of any depressive disorder, positive and negative affect scores, figural fluency, attention, and psychomotor speed after adjusting for potential confounders, although the magnitude of these associations was generally small. In genetic analyses, genetic risk scores for CRP (CRP_{GRS}) and GlycA_{GRS} were both associated with higher negative affect score. CRP_{GRS} was associated with any anxiety disorder whereas GlycA_{GRS} was associated with major depressive disorder. Inflammatory marker GRSs were not associated with cognitive task performance, except for soluble IL-6R_{GRS} which was associated with poorer memory performance. Individual level MR provided weak evidence for a causal effect of CRP on any anxiety disorder. Genetic and non-genetic analyses provided consistent evidence for an association, albeit small, of CRP on negative affect. Genetic analyses suggest that IL-6 signaling could be relevant for memory, and that the association between CRP and anxiety disorders could be potentially causal.

Affect

Inflammation has generally been associated with higher levels of negative affect and lower levels of positive affect, although findings are primarily based on medical populations^{72–74} and small community samples^{13,75}. To our knowledge, this is the first large, population-based study to find small but consistent associations of higher CRP with higher negative affect and lower positive affect, both unadjusted and adjusted for potential confounds. Interestingly, both CRP and GlycA genetic risk scores were associated with higher levels of negative affect, but not positive affect. This consistent association across non-genetic and genetic analyses may reflect the effect of inflammation on a range of emotional states beyond the cardinal features of depression (i.e., sadness/anhedonia), which aligns with prior research linking inflammation with fear and irritability^{51,76}. Prior work has shown that inflammation is differentially associated with a specific clinical presentation characterized by anhedonia and somatic/neurovegetative symptoms (e.g., fatigue, altered sleep and appetite changes) and further work is needed that more accurately characterize an inflammatory phenotype in depression^{77,78}.

Depression

These data add to a growing body of evidence evaluating the role of inflammation in the etiology of depression. The results of non-genetic analyses broadly aligns with results from the UK Biobank cohort in terms of (i) prevalence estimates of depression and anxiety, (ii) robust univariate associations between CRP and depression and anxiety, which were generally no longer statistically significant when controlling for covariates, and (iii) stronger univariate associations for CRP and depression when compared to anxiety³⁷. It has long been noted that variables being conceptualized as confounds that require statistical adjustment (e.g., BMI, medical illness) may, in fact, be key mechanisms in the pathophysiology of inflammatory depression^{79,80}. As such, attenuation of associations following adjustment for covariates would not, by itself, indicate a non-causal relationship. Indeed, inflammation may increase risk for depression via increasing the risk of inflammation-related physical multimorbidity (e.g., cardiovascular disease)³⁴ – a hypothesis that requires further investigation.

In genetic analyses, there was also little evidence of an association between CRP_{GRS} and depression outcomes, although there was evidence suggesting GlycA_{GRS} increases liability to MDD. The null CRP findings are consistent with previous MR studies showing no evidence of effect in MDD^{42,43,81}. However, the MR literature of CRP on depression is mixed with some studies reporting CRP to decrease³⁷ or increase³⁴ risk for depression. It is unclear what accounts for these mixed findings, but potential factors may include CRP SNP selection, definition and/or measurement of depression, statistical power, and selection bias (see Supplementary Discussion). In contrast, MR studies have shown more consistent findings for the potential causal role of IL-6 on depression^{35–37,82}. This is similar to MR findings for coronary heart disease, where IL-6 but not CRP have been shown to play a potential causal role^{83,84}. Consequently, studies on a broader range of immune markers (e.g. cytokines, immune cells) and specific immune pathways would be more useful to understand the role of inflammation in depression, rather than CRP which is a non-specific marker of systemic immune activation⁸⁵.

Cognition

We observed relatively small effects of CRP on cognitive task performance, and in genetic analysis only sIL-6R_{GRS} was associated with poor memory performance. Our findings contribute to inconsistent findings across population-based cohorts assessing circulating inflammatory biomarkers and cognitive performance where associations observed in population-based studies²⁵ often are not large in magnitude or consistently observed⁴⁴. Few MR studies have been conducted on the role of inflammation on cognition. Consistent with results presented here, our previous MR study examining the role of the same inflammatory markers (i.e., CRP, IL-6, IL-6R, sIL-6R, GlycA) on specific executive functions within the ALSPAC cohort (e.g., emotion recognition, working memory, response inhibition⁴⁴) found little evidence of a potential causal effect. However, Pagoni et al. recently reported that other cytokines and chemokines (i.e., Eotaxin, IL-8, MCP1) may be causally related to lower fluid intelligence (and IL-4 with higher fluid intelligence)⁴⁵. The finding regarding sIL-6R and memory performance is novel and would align with convergent evidence that trans-signaling – in which sIL-6R plays a critical role – may be responsible for the deleterious effect of IL-6 on cognitive functioning^{38,86}.

Interpreting the relationship between inflammation and cognitive task performance in population-based studies is difficult for several reasons. First, there is considerable heterogeneity in the cognitive abilities assessed across studies and there is a need for future studies to more uniformly include well-validated measures assessing individual differences, rather than detecting pathological states (e.g., dementia, epilepsy)]⁸⁷. There is a similar need to evaluate the impact that inflammation has on other psychological functions that impact cognition (e.g., reward process, aversive process) – there is strong theoretical work and empirical data to support an indirect effect of inflammation on cognition via, for instance, dysregulated reward circuitry that impact performance on cognitive tasks via decreased motivation or increased fatigue⁸⁸. Moreover, there are a range of sociodemographic factors that may moderate the association between inflammation and cognition – prior work has found that inflammation and cognition may differ based on age and sex^{89,90}. It is reasonable to assume, for instance, that modest increases in inflammation may exert a cumulative effect across the lifespan, and thus may only be detected later in life and/or in specific domains of cognition.

Anxiety

In the non-genetic analyses, circulating CRP levels was associated with a modestly increased likelihood of meeting criteria for anxiety disorders, although this association was substantially attenuated following adjustments for covariates. Prior research in population-based cohorts have found CRP to associated with an increased risk for anxiety disorders^{91,92}, although results are inconsistent and other studies indicate that anxiety prospectively predicts an increase in circulating CRP levels⁹³. The MR analysis suggests a potential causal role of CRP on any anxiety disorder (which covers a broad range of anxiety-related conditions including panic disorder, social phobia, agoraphobia, GAD). Prior theory has primarily focused on anxiety as a cause of inflammation⁹⁴; however, alternative theories suggest that inflammatory physiology is implicated in both sickness behaviors (e.g., anhedonia, social withdrawal) and anxiety arousal and alarm⁹⁵, which would align with the results presented here.

Limitations

This study used a large and population-based sample that employed triangulation of genetic and non-genetic analyses, which increases confidence in the inferences drawn. Limitations, however, exist. First, although broadly representative, like other cohort studies (e.g., UK Biobank), the Lifelines cohort predominantly includes individuals of European descent and is less representative of individuals from low socioeconomic status⁹⁶, which consequentially limits the generalizability of findings. Second, analyses were not corrected for multiple comparisons and are in need of replication. Moreover, as effect sizes reported are small and reflect associations in the general population, there is a need for studies to investigate whether there are sub-groups for whom these associations may be larger (e.g., older age, clinical populations). Third, in the genetic analysis the CRP GRS explained 1–4% of the variance in CRP [a level of variance consistent with similar analyses in the ALSPAC cohort⁴⁴] and few cases of depression were observed in Lifelines [although the point prevalence of approximately 4% is consistent with reported population point prevalence estimates⁹⁷]. It is possible that this limited our capacity to detect potential causal effects, were they small in magnitude or non-linear. Fourth, the CogState tasks used in the current study may not be optimal for detecting individual differences in healthy individuals, or even in some conditions such as depression; multiple studies have shown that the CogState tasks used in this study do not improve in successful antidepressant trials, even when improvement in other cognitive measures are observed^{98–100}. Fifth, although we include multiple instruments related to IL-6 (i.e., genetic variants related to IL-6 and sIL-6R levels), most instruments contain few genetic variants (≤ 3 SNPs) and genetic variants for IL-6 and sIL-6R overlap. While sIL-6R is involved in IL-6 trans-signaling, the overlap of SNPs makes it challenging to interpret the effect of these genetic variants on different immune phenotypes specifically (i.e., IL-6 levels vs IL-6 signaling). Future studies are needed to better understand the biological role of these genetic variants and develop instruments proxying specific IL-6 signaling pathways including IL-6 trans-signaling. Finally, it is worth considering that some instruments in the genetic analyses were associated with potential confounds.

Conclusions

Genetic and non-genetic analyses provide consistent evidence for a modest effect of CRP on negative affect. Genetic analyses suggest that IL-6 signaling could be relevant for memory, and that the association between CRP and anxiety disorders could be causal. Overall, these results suggest that inflammation may affect a range of emotional states beyond the cardinal features of depression. However, given the small effect sizes and multiple tests conducted, future studies should investigate whether effects are moderated by sub-groups and whether these findings replicate in other cohorts.

Declarations

Conflict of Interest

No conflicts of interest were reported.

Funding

This work was supported by Harvard University's Mind Brain Behavior Interfaculty Initiative and National Institute of Mental Health grant K23MH132893 (Dr. Mac Giollabhui), and a UK Medical Research Council (MRC) grant to GMK (MC_UU_00032/06) which forms part of the Integrative Epidemiology Unit (IEU) at the University of Bristol. The MRC grant also supports CS and EMF. GMK acknowledges additional funding support from the Wellcome Trust (201486/Z/16/Z and 201486/B/16/Z), MRC (MR/W014416/1; MR/S037675/1; and MR/Z50354X/1), and the UK National Institute of Health and Care Research (NIHR) Bristol Biomedical Research Centre (NIHR 203315). GH and GDS are supported by the MRC (MC_UU_00032/01), and the NIHR Bristol Biomedical Research Centre (NIHR 203315). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care, UK.

Acknowledgments

The Lifelines initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG), Groningen University and the Provinces in the North of the Netherlands (Drenthe, Friesland, Groningen). The generation and management of GWAS genotype data for the Lifelines Cohort Study is supported by the UMCG Genetics Lifelines Initiative (UGLI). UGLI is partly supported by a Spinoza Grant from NWO, awarded to Cisca Wijmenga. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants.

References

1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M *et al*. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2020; **396**(10258): 1204-1222.
2. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N *et al*. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet* 2018; **392**(10159): 1789-1858.
3. Taylor CA, Boudin ED, McGuire LC. Subjective Cognitive Decline Among Adults Aged ≥ 45 Years - United States, 2015-2016. *MMWR Morb Mortal Wkly Rep* 2018; **67**(27): 753-757.
4. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. *Int Rev Psychiatry* 2014; **26**(1): 102-113.
5. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM *et al*. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun* 2022; **101**: 93-135.
6. Wang Y, Liu M, Lu Q, Farrell M, Lappin JM, Shi J *et al*. Global prevalence and burden of HIV-associated neurocognitive disorder. *A meta-analysis* 2020; **95**(19): e2610-e2621.
7. Barreira DP, Marinho RT, Bicho M, Fialho R, Ouakinin SRS. Psychosocial and Neurocognitive Factors Associated With Hepatitis C - Implications for Future Health and Wellbeing. *Front Psychol* 2018; **9**: 2666.
8. Fava M, Mahableshwarkar AR, Jacobson W, Zhong W, Keefe RS, Olsen CK *et al*. What is the overlap between subjective and objective cognitive impairments in MDD? *Ann Clin Psychiatry* 2018; **30**(3): 176-184.
9. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. *Novel antischizophrenia treatments* 2012: 11-37.
10. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L *et al*. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. *Am J Psychiatry* 2006; **163**(1): 28-40.
11. Fesharaki-Zadeh A, Lowe N, Arnsten AFT. Clinical experience with the $\alpha 2A$ -adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in "Long-COVID19". *Neuroimmunology Reports* 2023; **3**: 100154.
12. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK *et al*. A meta-analysis of cytokines in major depression. *Biol Psychiatry* 2010; **67**(5): 446-457.
13. Ironson G, Banerjee N, Fitch C, Krause N. Positive emotional well-being, health Behaviors, and inflammation measured by C-Reactive protein. *Soc Sci Med* 2018; **197**: 235-243.
14. Felger JC, Treadway MT. Inflammation Effects on Motivation and Motor Activity: Role of Dopamine. *Neuropsychopharmacology* 2017; **42**(1): 216-241.
15. Mac Giollabhui N, Ng TH, Ellman LM, Alloy LB. The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression. *Mol Psychiatry* 2021; **26**(7): 3302-3314.
16. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA. Association of C-reactive protein with cognitive impairment. *Arch Neurol* 2010; **67**(1): 87-92.
17. Baune B, Ponath G, Golledge J, Varga G. Association between IL-8 cytokine and cognitive performance in an elderly general population—the MEMO-Study. *Neurobiol Aging* 2008; **29**(6): 937-944.

18. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A *et al.* Cytokine-associated emotional and cognitive disturbances in humans. *Arch Gen Psychiatry* 2001; **58**(5): 445-452.
19. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A *et al.* Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. *Neurology* 2014; **83**(6): 486-493.
20. Crisan AF, Oancea C, Timar B, Fira-Mladinescu O, Crisan A, Tudorache V. Cognitive impairment in chronic obstructive pulmonary disease. *PLoS One* 2014; **9**(7): e102468.
21. Huang YS, Guilleminault C, Hwang FM, Cheng C, Lin CH, Li HY *et al.* Inflammatory cytokines in pediatric obstructive sleep apnea. *Medicine* 2016; **95**(41): e4944.
22. Mac Giollabhui N. Inflammation and depression: Research designs to better understand the mechanistic relationships between depression, inflammation, cognitive dysfunction, and their shared risk factors. *Brain Behav Immun Health* 2021; **15**: 100278.
23. Krogh J, Benros ME, Jorgensen MB, Vesterager L, Elfving B, Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. *Brain Behav Immun* 2014; **35**: 70-76.
24. Goldsmith DR, Haroon E, Woolwine BJ, Jung MY, Wommack EC, Harvey PD *et al.* Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. *Brain Behav Immun* 2016; **56**: 281-288.
25. Mac Giollabhui N, Alloy LB, Hartman CA. Investigating whether depressed youth exhibiting elevated C reactive protein perform worse on measures of executive functioning, verbal fluency and episodic memory in a large, population based sample of Dutch adolescents. *Brain Behav Immun* 2021; **94**: 369-380.
26. Mac Giollabhui N, Swiston D, Murray S, Moriarity DP, Kautz MM, Ellman LM *et al.* Executive dysfunction in depression in adolescence: the role of inflammation and higher body mass. *Psychol Med* 2020; **50**(4): 683-691.
27. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. *Neurosci Biobehav Rev* 2009; **33**: 355-366.
28. Carvalho AF, Miskowiak KK, Hyphantis TN, Kohler CA, Alves GS, Bortolato B *et al.* Cognitive dysfunction in depression - pathophysiology and novel targets. *CNS Neurol Disord Drug Targets* 2014; **13**(10): 1819-1835.
29. Chesnokova V, Pechnick RN, Wawrowsky K. Chronic peripheral inflammation, hippocampal neurogenesis, and behavior. *Brain Behav Immun* 2016; **58**: 1-8.
30. Goldsmith D, Bekhbat M, Mehta ND, Felger JC. Inflammation-related functional and structural dysconnectivity as a pathway to psychopathology. *Biol Psychiatry* 2023; **93**(4): 405-418.
31. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. *Biol Psychiatry* 2010; **68**(8): 748-754.
32. Harrison NA, Cercignani M, Voon V, Critchley HD. Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants. *Neuropsychopharmacology* 2015; **40**(4): 831-838.
33. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 2003; **32**(1): 1-22.
34. Khandaker GM, Zuber V, Rees JMB, Carvalho L, Mason AM, Foley CN *et al.* Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol Psychiatry* 2020; **25**(7): 1477-1486.
35. Perry BI, Upthegrove R, Kappelmann N, Jones PB, Burgess S, Khandaker GM. Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study. *Brain Behav Immun* 2021; **97**: 176-185.
36. Kelly KM, Smith JA, Mezuk B. Depression and interleukin-6 signaling: A Mendelian Randomization study. *Brain Behav Immun* 2021; **95**: 106-114.
37. Ye Z, Kappelmann N, Moser S, Smith GD, Burgess S, Jones PB *et al.* Role of Inflammation in Depression and Anxiety: Tests for Disorder Specificity, Linearity and Potential Causality of Association in the UK Biobank. *medRxiv* 2021.
38. Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. *Nat Rev Immunol* 2023; **23**(10): 666-681.
39. Crick DC, Khandaker GM, Halligan SL, Burgner D, Mansell T, Fraser A. Comparison of the stability of glycoprotein acetyls and high sensitivity C-reactive protein as markers of chronic inflammation. *Immunology* 2023.
40. Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S *et al.* Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. *JAMA Psychiatry* 2020.
41. Crick DCP, Sanderson E, Jones H, Goulding N, Borges MC, Clayton G *et al.* Glycoprotein acetyls and depression: Testing for directionality and potential causality using longitudinal data and Mendelian randomization analyses. *J Affect Disord* 2023; **335**: 431-439.
42. Bekkevold O-J, Damås JK, Brumpton BM, Åsvold BO. The causal role of C-reactive protein and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation analyses in the HUNT study. *Psychol Med* 2023: 1-8.
43. Galan D, Perry BI, Warrier V, Davidson CC, Stupart O, Easton D *et al.* Applying Mendelian randomization to appraise causality in relationships between smoking, depression and inflammation. *Sci Rep* 2022; **12**(1): 15041.
44. Slaney C, Sallis HM, Jones HJ, Dardani C, Tilling K, Munafo MR *et al.* Association between inflammation and cognition: Triangulation of evidence using a population-based cohort and Mendelian randomization analyses. *Brain Behav Immun* 2023; **110**: 30-42.
45. Pagoni P, Korologou-Linden RS, Howe LD, Davey Smith G, Ben-Shlomo Y, Stergiakouli E *et al.* Causal effects of circulating cytokine concentrations on risk of Alzheimer's disease and cognitive function. *Brain Behav Immun* 2022; **104**: 54-64.

46. Fleshner M, Frank M, Maier SF. Danger Signals and Inflammasomes: Stress-Evoked Sterile Inflammation in Mood Disorders. *Neuropsychopharmacology* 2017; **42**(1): 36-45.
47. Slavich GM. Social safety theory: a biologically based evolutionary perspective on life stress, health, and behavior. *Annu Rev Clin Psychol* 2020; **16**.
48. Murphy K, Weaver C. *Janeway's Immunobiology (9th Edition)*. Garland Science, Taylor & Francis Group: New York, New York, 2017.
49. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. *Am J Psychiatry* 2015; **172**(11): 1075-1091.
50. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* 2016; **16**(1): 22-34.
51. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. *Psychol Bull* 2014; **140**(3): 774-815.
52. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM *et al*. Cohort Profile: LifeLines, a three-generation cohort study and biobank. *Int J Epidemiol* 2015; **44**(4): 1172-1180.
53. Ross TP. The reliability and convergent and divergent validity of the Ruff Figural Fluency Test in healthy young adults. *Arch Clin Neuropsychol* 2014; **29**(8): 806-817.
54. Mac Giollabhui N, Alloy LB, Schwenen LJS, Hartman CA. Investigating whether a combination of higher CRP and depression is differentially associated with worse executive functioning in a cohort of 43,896 adults. *Brain Behav Immun* 2021; **96**: 127-134.
55. Overbeek T, Schruers K, Griez E. MINI: Mini international neuropsychiatric interview, Dutch version 5.0. 0 (DSM-IV). *Maastricht: University of Maastricht* 1999.
56. Hergueta T, Weiller E. *MINI-S for DSM-5, Dutch version*, 2017.
57. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan K *et al*. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI. *Eur Psychiatry* 1997; **12**(5): 224-231.
58. Wanders RB, van Loo HM, Vermunt JK, Meijer RR, Hartman CA, Schoevers RA *et al*. Casting wider nets for anxiety and depression: disability-driven cross-diagnostic subtypes in a large cohort. *Psychol Med* 2016; **46**(16): 3371-3382.
59. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol* 1988; **54**(6): 1063.
60. Crawford JR, Henry JD. The Positive and Negative Affect Schedule (PANAS): Construct validity, measurement properties and normative data in a large non-clinical sample. *Br J Clin Psychol* 2004; **43**(3): 245-265.
61. ieuGWAS: Interface to the 'OpenGWAS' Database API. R package version 0.2.2-9000. 2024, Accessed Date Accessed 2024 Accessed.
62. Said S, Pazoki R, Karhunen V, Vösa U, Ligthart S, Bodinier B *et al*. Genetic analysis of over half a million people characterises C-reactive protein loci. *Nat Commun* 2022; **13**(1): 2198.
63. Collaboration IRGCERF, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P *et al*. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet* 2012; **379**(9822): 1205-1213.
64. Project IOG. Glycoprotein acetyls Dataset: met-d-GlycA. 2023.
65. Swordlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J *et al*. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. *Int J Epidemiol* 2016; **45**(5): 1600-1616.
66. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics* 2015; **31**(21): 3555-3557.
67. Myers TA, Chanock SJ, Machiela MJ. LDlinkR: An R Package for Rapidly Calculating Linkage Disequilibrium Statistics in Diverse Populations. *Frontiers in Genetics* 2020; **11**.
68. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al*. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**(3): 559-575.
69. Aulchenko YS, De Koning D-J, Haley C. Genomewide rapid association using mixed model and regression: a fast and simple method for genomewide pedigree-based quantitative trait loci association analysis. *Genetics* 2007; **177**(1): 577-585.
70. Kleiber C, Zeileis A. *Applied econometrics with R*. Springer Science & Business Media 2008.
71. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* 2011; **40**(3): 755-764.
72. Slavich DC, Jones DR, Smyth JM, Engeland CG, Song S, McCormick NM *et al*. Positive and Negative Affect and Salivary Markers of Inflammation Among Young Adults. *Int J Behav Med* 2020; **27**(3): 282-293.
73. Brouwers C, Mommersteeg PM, Nyklíček I, Pelle AJ, Westerhuis BL, Szabó BM *et al*. Positive affect dimensions and their association with inflammatory biomarkers in patients with chronic heart failure. *Biol Psychol* 2013; **92**(2): 220-226.
74. Sepah SC, Bower JE. Positive affect and inflammation during radiation treatment for breast and prostate cancer. *Brain Behav Immun* 2009; **23**(8): 1068-1072.
75. Stellar JE, John-Henderson N, Anderson CL, Gordon AM, McNeil GD, Keltner D. Positive affect and markers of inflammation: discrete positive emotions predict lower levels of inflammatory cytokines. *Emotion* 2015; **15**(2): 129.
76. Boylan JM, Lewis TT, Coe CL, Ryff CD. Educational Status, Anger, and Inflammation in the MIDUS National Sample: Does Race Matter? *Ann Behav Med* 2015; **49**(4): 570-578.

77. Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB *et al.* Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts. *Mol Psychiatry* 2021; **26**(12): 7393-7402.
78. Milaneschi Y, Lamers F, Berk M, Penninx B. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. *Biol Psychiatry* 2020; **88**(5): 369-380.
79. Felger JC, Haroon E, Miller AH. What's CRP got to do with it? Tackling the complexities of the relationship between CRP and depression. *Brain Behav Immun* 2018; **73**: 163-164.
80. Mac Giollabhui N, Ellman LM, Coe CL, Byrne ML, Abramson LY, Alloy LB. To exclude or not to exclude: Considerations and recommendations for C-reactive protein values higher than 10 mg/L. *Brain Behav Immun* 2020; **87**: 898-900.
81. Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG. Elevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73 131 Individuals. *JAMA Psychiatry* 2013; **70**: 176.
82. Khandaker GM, Zuber V, Rees JM, Carvalho L, Mason AM, Foley CN *et al.* Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol Psychiatry* 2019: 1-10.
83. Consortium I-RMRA. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *The Lancet* 2012; **379**(9822): 1214-1224.
84. Collaboration CRPCHDG. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *BMJ* 2011; **342**.
85. Foley ÉM, Slaney C, Donnelly NA, Kaser M, Ziegler L, Khandaker GM. A novel biomarker of interleukin 6 activity and clinical and cognitive outcomes in depression. *Psychoneuroendocrinology* 2024; **164**: 107008.
86. Mac Giollabhui N, Foster S, Lowry CA, Mischoulon D, Raison CL, Nyer M. Interleukin-6 receptor antagonists in immunopsychiatry: Can they lead to increased interleukin-6 in the central nervous system (CNS) and worsening psychiatric symptoms? *Brain Behav Immun* 2022; **103**: 202-204.
87. Boogert NJ, Madden JR, Morand-Ferron J, Thornton A. Measuring and understanding individual differences in cognition. *Philos Trans R Soc Lond B Biol Sci* 2018; **373**(1756).
88. Mac Giollabhui N, Mischoulon D, Dunlop BW, Kinkead B, Schettler PJ, Liu RT *et al.* Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial. *Brain Behav Immun Health* 2023; **32**: 100666.
89. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol* 2016; **16**(10): 626-638.
90. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol* 2018; **15**(9): 505-522.
91. Vogelzangs N, Beekman ATF, de Jonge P, Penninx BWJH. Anxiety disorders and inflammation in a large adult cohort. *Transl Psychiatry* 2013; **3**(4): e249-e249.
92. Costello H, Gould RL, Abrol E, Howard R. Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder. *BMJ open* 2019; **9**(7): e027925.
93. Glaus J, von Känel R, Lasserre AM, Strippoli MPF, Vandeleur CL, Castelao E *et al.* The bidirectional relationship between anxiety disorders and circulating levels of inflammatory markers: results from a large longitudinal population-based study. *Depress Anxiety* 2018; **35**(4): 360-371.
94. O'Donovan A, Slavich GM, Epel ES, Neylan TC. Exaggerated neurobiological sensitivity to threat as a mechanism linking anxiety with increased risk for diseases of aging. *Neurosci Biobehav Rev* 2013; **37**(1): 96-108.
95. Raison CL, Miller AH. Pathogen–host defense in the evolution of depression: insights into epidemiology, genetics, bioregional differences and female preponderance. *Neuropsychopharmacology* 2017; **42**(1): 5-27.
96. Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N. Representativeness of the LifeLines Cohort Study. *PLoS One* 2015; **10**(9): e0137203.
97. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M *et al.* Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2020; **396**(10258): 1204-1222.
98. Freeman MP, Cheng LJ, Moustafa D, Davies A, Sosinsky AZ, Wang B *et al.* Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. *Ann Clin Psychiatry* 2017; **29**(4): 249-257.
99. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. *Neuropsychopharmacology* 2015; **40**(8): 2025-2037.
100. Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR. Quetiapine augmentation in depressed patients with partial response to antidepressants. *Hum Psychopharmacol* 2008; **23**(8): 653-660.

Figures





Figure 1

Associations of genetic risk scores for inflammatory markers with mood, anxiety disorders and positive and negative affect scores.


A) Detection Task (reaction time; N=35,300)

B) Identification Task (reaction time; N=35,729)



C) One-back Task (accuracy; N=36,349)

D) One Card Learning Task (accuracy; N=36,783)



E) RFFT (N=36,563)






Figure 2

Associations of genetic risk scores for inflammatory markers with cognitive task performance.

CRP association with mental health and cognition in the Lifelines Cohort

	CRP Levels	CRP <i>cis</i> Genetic Risk Score
 Mood Disorder/ Affect	Major Depressive Disorder	↑
	Any Depressive Disorder	↑
	Generalised Anxiety Disorder	↑
	Any Anxiety Disorder	↑
	Negative Affect	↑
	Positive Affect	↓
 Cognition	Executive Function	↓
	Attention (RT)	↑
	Psychomotor speed (RT)	↑
	Episodic memory	...
	Working memory	↓

Arrows indicate direction of effect. Solid arrows ($p < .05$), dashed arrows ($p > .05$).

Positive arrows = increased liability to mood disorder/affect and better cognitive performance, except for reaction time (RT) measures where positive score = higher RT (i.e., slower response). All mood disorder measures are from Baseline assessment where sample size is largest. Non-genetic results = adjusted analysis.

Figure 3

Visualisation of the overall pattern of results for CRP in the cohort and genetic analyses

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementary05062024.docx](#)